Treatment outcomes of risperidone long acting injection (RLAI) in schizophrenia: 18-month results from the electronic schizophrenia treatment adherence registry (E-STAR) in Czech Republic and Slovakia

被引：0

作者：

Tuma, I ^{[1
]}

Pecenak, J. ^{[2
]}

Povey, M. ^{[3
]}

Lam, A. ^{[4
]}

Zhao, Z. ^{[5
]}

机构：

[1] FNSP Hradec Kralove, Hradec Kralove, Czech Republic

[2] FNSP Bratislava, Bratislava, Slovakia

[3] SGS Biopharma, Wavre, Belgium

[4] JJPS, Toronto, ON, Canada

[5] Johnson & Johnson Pharmaceut Serv, Raritan, NJ USA

来源：

VALUE IN HEALTH | 2008年 / 11卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)70362-4

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A112 / A113

页数：2

共 50 条

[11] Remission in patients with schizophrenia treated with risperidone long-acting injection:: Results from the e-STAR project in Czech Republic and Slovakia
Pecenak, J.
Tuma, I.
Povey, M.
Lam, A.
EUROPEAN PSYCHIATRY, 2008, 23 : S162 - S162
[12] Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)
Olivares, J. M.
Rodriguez-Morales, A.
Diels, J.
Povey, M.
Jacobs, A.
Zhao, Z.
Lam, A.
EUROPEAN PSYCHIATRY, 2009, 24 (05) : 287 - 296
[13] Patient and physician satisfaction with risperidone long-acting injection: 18-month interim results from the electronic schizophrenia treatment adherence registry in Belgium
Peuskens, J.
Povey, M.
Van der Veken, J.
Jacobs, A.
Lam, A.
EUROPEAN PSYCHIATRY, 2008, 23 : S163 - S163
[14] Reduced polypharmacy in patients enrolled in the electronic schizophrenia adherence registry (E-STAR) and treated with risperidone long-acting injection (RLAI) for 6 months
Peusekens, J.
Olivares, J. M.
Hustig, H.
Povey, M.
Jacobs, A.
EUROPEAN PSYCHIATRY, 2007, 22 : S116 - S117
[15] Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada
Williams, Richard
Chandrasena, Ranjith
Beauclair, Linda
Luong, Doanh
Lam, Annette
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 417 - 425
[16] Remission in patients with schizophrenia treated with risperidone long-acting injection (FLAI): 12 month interim results from e-STAR project in Czech Republic and Slovakia
Tuma, I
Pecenak, J.
Povey, M.
Lam, A.
VALUE IN HEALTH, 2007, 10 (06) : A291 - A291
[17] Six-month follow-up from the electronic-schizophrenia adherence treatment registry (e-STAR) of patients in Spain who were initiated to risperidone long-acting injection (RLAI)
Olivares, J.
Rodriguez, A.
Povey, M.
Diels, J.
Jacobs, A.
VALUE IN HEALTH, 2006, 9 (06) : A320 - A321
[18] The Electronic Schizophrenia Treatment Adherence Registry - E-STAR: Baseline results for Germany
Naber, D
Mehnert, A
Rosillon, D
Farmer, D
Schreiner, A
Jacobs, A
VALUE IN HEALTH, 2005, 8 (03) : 402 - 403
[19] Reduction in suicidal ideation, violent behaviour, and self injury after treatment with risperidone long-acting injection (RLAI): 12 month preliminary results from e-STAR project in Czech Republic and Slovakia
Tuma, I
Pecenak, J.
Povey, M.
Lam, A.
VALUE IN HEALTH, 2007, 10 (06) : A290 - A290
[20] Comparative effectiveness of risperidone long-acting injection (RLAI) and oral antipsychotics in schizophrenia patients enrolled in the electronic schizophrenia adherence registry (E-STAR) in Spain: An evaluation based on propensity scoring
Diels, J.
Olivares, J. M.
Rodriguez-Morales, A.
Caleo, S.
JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2007, 10 : S11 - S11

← 1 2 3 4 5 →